TNF and respiratory tract infectious disorder: This study corroborates the infection risk warnings for TNF-α inhibitors previously reported by Krabbe [27], while uniquely identifying clostridioides difficile infection as a predominant pediatric safety concern, contrasting with prior adult-focused studies emphasizing respiratory infections.